Arrowhead Pharmaceuticals Inc (ARWR)vsModerna Inc (MRNA)
ARWR
Arrowhead Pharmaceuticals Inc
$60.21
+2.00%
HEALTHCARE · Cap: $7.90B
MRNA
Moderna Inc
$214.17
+2.98%
HEALTHCARE · Cap: $87.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 233% more annual revenue ($2.23B vs $669.50M). ARWR leads profitability with a -47.8% profit margin vs -141.4%. ARWR earns a higher WallStSmart Score of 32/100 (F).
ARWR
Avoid32
out of 100
Grade: F
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for ARWR.
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$214.16
$79.45 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 171.0% year-over-year
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Trading at 18.2x book value
Elevated debt levels
ROE of -68.7% — below average capital efficiency
Negative free cash flow — burning cash
Trading at 12.6x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ARWR
The strongest argument for ARWR centers on Revenue Growth. Revenue growth of 171.0% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ARWR
The primary concerns for ARWR are Price/Book, Debt/Equity, Return on Equity. Debt-to-equity of 1.86 is elevated, increasing financial risk.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ARWR profiles as a hypergrowth stock while MRNA is a turnaround play — different risk/reward profiles.
ARWR carries more volatility with a beta of 1.30 — expect wider price swings.
ARWR is growing revenue faster at 171.0% — sustainability is the question.
ARWR generates stronger free cash flow (-181M), providing more financial flexibility.
Bottom Line
ARWR scores higher overall (32/100 vs 21/100) and 171.0% revenue growth. MRNA offers better value entry with a 69.9% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Arrowhead Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Arrowhead Pharmaceuticals, Inc. develops drugs for the treatment of intractable diseases in the United States. The company is headquartered in Pasadena, California.
Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?